Akebia Therapeutics prices public offering of 25 million shares at $2 each

From GlobeNewswire: 2025-03-19 22:17:53

Akebia Therapeutics, Inc. announced the pricing of its underwritten public offering of 25,000,000 shares of common stock at $2.00 per share, totaling $50.0 million in gross proceeds. The Offering, expected to close on March 21, 2025, includes an option for underwriters to purchase an additional 3,750,000 shares. The joint bookrunning managers are Leerink Partners and Piper Sandler & Co., with BTIG, LLC as lead manager and H.C. Wainwright & Co. as co-manager. The shares are being offered under a shelf registration statement filed with the SEC. More details on the Offering can be found on the SEC’s website.

Akebia Therapeutics, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company dedicated to improving the lives of individuals affected by kidney disease. The Offering is subject to customary closing conditions and was made in accordance with a prospectus and prospectus supplement. This press release does not constitute an offer to sell securities, and interested parties should refer to the SEC for more information. Akebia’s forward-looking statements in this press release are subject to risks and uncertainties, with additional information available in their filings with the SEC.



Read more at GlobeNewswire: Akebia Therapeutics Announces Pricing of Public Offering of